Johnson & Johnson (JNJ)

131.31
0.67 0.51
NYSE : Health Technology
Prev Close 131.98
Open 132.00
Day Low/High 131.02 / 132.09
52 Wk Low/High 121.00 / 148.99
Volume 5.20M
Avg Volume 7.68M
Exchange NYSE
Shares Outstanding 2.63B
Market Cap 350.04B
EPS 5.70
P/E Ratio 25.33
Div & Yield 3.80 (2.82%)

Latest News

Amazon Is a Trade for Now, The Fed Pipes Down: Market Recon

Amazon Is a Trade for Now, The Fed Pipes Down: Market Recon

Most important is that the Fed felt the need earlier this week to expand it's minimum offering for overnight repo operations, while also increasing the 14 day repos.

Is the Worst Over for Johnson & Johnson?

Is the Worst Over for Johnson & Johnson?

A lot of investing is just waiting until the market hates good companies.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

Earnings Season Round 2 Starts Today

Earnings Season Round 2 Starts Today

The majority of the S&P 500 stocks will report in the next two weeks. Focus on individual stock picking, but keep stops tight.

Energy Stocks Are Getting Hammered

Energy Stocks Are Getting Hammered

There are myriad concerns across the energy complex, the most prevalent one centered around declining global growth reducing the demand for energy.

China Trade, Next Brexit Vote, Fed Action, Trading Lockheed: Market Recon

China Trade, Next Brexit Vote, Fed Action, Trading Lockheed: Market Recon

The Trump and Xi administrations are at least looking at the same page. That's more than nothing.

3 Earnings Reports Will Be Key for the Market Next Week

3 Earnings Reports Will Be Key for the Market Next Week

There is a good foundation for more positive action in the week ahead.

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Before I give my recommendation I want to visit with the charts and indicators.

For Boeing and Johnson & Johnson: Where There's Smoke, There's Fire

For Boeing and Johnson & Johnson: Where There's Smoke, There's Fire

Both BA and JNJ appear to have made decisions in which the bottom line took precedent over what they stand for as a company.

Jim Cramer: Here's How You Get a Not as Bad as Feared Quarter

Jim Cramer: Here's How You Get a Not as Bad as Feared Quarter

I have the answer behind the conundrum that forces stocks up that should be going lower.

Jim Cramer: Netflix and CSX Lead the 'NABAF' Earnings Story

Jim Cramer: Netflix and CSX Lead the 'NABAF' Earnings Story

These stocks's earnings were 'not as bad as feared,' and here are some more names that pushed the NABAF narrative.

Jim Cramer: The Market Is Lapping Up These Stocks

Jim Cramer: The Market Is Lapping Up These Stocks

There are plenty of senior growth companies that can still move higher.

Key Market Observations

As mentioned earlier, breadth was only 2-1 positive with UnitedHealth , JPMorgan and Johnson & Johnson responsible for a large portion of the market's gains. Bond yields rose, aiding the rate-sensitive banks (who generally met expectations). FANG ha...

Jim Cramer: Here's What We Can Bask in Today

Jim Cramer: Here's What We Can Bask in Today

On days like today you realize how much of this market has been mauled by the bear.

Advancers Over Decliners

"Only" about 2-1 advancers over decliners as UnitedHealth Care , JP Morgan and Johnson & Johnson account for a disproportionate amount of the market's rally.

Valuation and 2 Names to Watch Into Earnings: Market Recon

Valuation and 2 Names to Watch Into Earnings: Market Recon

Citigroup and Lululemon are on the radar this morning.

Fed 'Blindsided' Again, Peloton's No Bargain, Trading Jabil: Market Recon

Fed 'Blindsided' Again, Peloton's No Bargain, Trading Jabil: Market Recon

Does the Fed just keep injecting liquidity into money markets every single night forever?

Jim Cramer: Here's Why the Market's So Feckless and Reactive

Jim Cramer: Here's Why the Market's So Feckless and Reactive

So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.

For Wealth and Safety Invest With a 'Shark'

For Wealth and Safety Invest With a 'Shark'

Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.

Historical Litigation Risk at JNJ

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Johnson & Johnson's Fine May Be the Pin Prick That Keeps Bleeding

Johnson & Johnson's Fine May Be the Pin Prick That Keeps Bleeding

By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.

Johnson & Johnson Is in the News, but How Do the Charts Look?

Johnson & Johnson Is in the News, but How Do the Charts Look?

I am not focused on today's price movement of the stock but the pattern from the end of 2017.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

3 Stocks That Would Be Hurt by a Strong Dollar

3 Stocks That Would Be Hurt by a Strong Dollar

3M, Caterpillar and Johnson & Johnson all face headwinds with a strong dollar.

Charts of Alcon Look Good

Charts of Alcon Look Good

Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.